Abstract
Background: Diabetic nephropathy (DN) is one of the foremost causes of mortality in diabetic patients as a result of increased urinary albumin excretion (UAE) rate and compromised renal function.
Introduction: Determination of increased excretion of albumin in urine chiefly attribute to the onset and progression of DN. However, due to certain limitations of albuminuria, the search for more sensitive, specific and reliable renal biomarkers is required for early prediction of DN.
Methods: Bibliographic investigation was made to scrutinize the data reporting relevant biomarkers associated with DN and may be used to predict the onset and progression of nephropathy.
Result and Conclusion: Optimization of biomarkers for a clinical situation requires a prospective validation in large numbers of patients with diabetic nephropathy and needs to be performed in different critically ill populations.
Keywords: Albuminuria, biomarkers, diabetic nephropathy, diagnostic method, emerging biomarkers, albumin.
Current Diabetes Reviews
Title:Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Volume: 13 Issue: 6
Author(s): Lalit Kishore, Navpreet Kaur and Randhir Singh*
Affiliation:
- M.M. College of Pharmacy, Maharishi Markandeshwar University, Mullana-Ambala, Haryana 133207,India
Keywords: Albuminuria, biomarkers, diabetic nephropathy, diagnostic method, emerging biomarkers, albumin.
Abstract: Background: Diabetic nephropathy (DN) is one of the foremost causes of mortality in diabetic patients as a result of increased urinary albumin excretion (UAE) rate and compromised renal function.
Introduction: Determination of increased excretion of albumin in urine chiefly attribute to the onset and progression of DN. However, due to certain limitations of albuminuria, the search for more sensitive, specific and reliable renal biomarkers is required for early prediction of DN.
Methods: Bibliographic investigation was made to scrutinize the data reporting relevant biomarkers associated with DN and may be used to predict the onset and progression of nephropathy.
Result and Conclusion: Optimization of biomarkers for a clinical situation requires a prospective validation in large numbers of patients with diabetic nephropathy and needs to be performed in different critically ill populations.
Export Options
About this article
Cite this article as:
Kishore Lalit , Kaur Navpreet and Singh Randhir*, Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy, Current Diabetes Reviews 2017; 13 (6) . https://dx.doi.org/10.2174/1573399812666161207123007
DOI https://dx.doi.org/10.2174/1573399812666161207123007 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy
Current Medicinal Chemistry Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Patent Annotations
Recent Patents on Inflammation & Allergy Drug Discovery Novel Therapeutic Strategies for Cardiorenal Protection in Patients with Type 2 Diabetes and Chronic Kidney Disease
Current Vascular Pharmacology Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study)
Current Diabetes Reviews Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research